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The modulation of the immune system can have multiple applications such as can-
cer treatment, and a wide type of processes involving inflammation where the potent 
chemotactic agent cyclophilin A (Cyp A) is implicated. The Porifera phylum, in which 
Spongionella is encompassed, is the main producer of marine bioactive compounds. 
Four secondary metabolites obtained from Spongionella (Gracilin H, A, L, and 
Tetrahydroaplysulphurin-1) were described to hit Cyp A and to block the release of 
inflammation mediators. Based on these results, some role of Spongionella compounds 
on other steps of the signaling pathway mediated by this chemotactic agent can be 
hypothesized. In the present paper, we studied the effect of these four compounds on 
the surface membrane CD147 receptor expression, on the extracellular levels of Cyp A 
and on the ability to migrate of concanavalin (Con A)-activated T lymphocytes. Similar 
to a well-known immunosuppressive agent cyclosporine A (CsA), Gracilin H, A, L, and 
tetrahydroaplysulphurin-1 were able to reduce the CD147 membrane expression and 
to block the release of Cyp A to the medium. Besides, by using Cyp A as chemotactic 
agent, T cell migration was inhibited when cells were previously incubated with Gracilin 
A and Gracilin L. These positive results lead us to test the in vivo effect of Gracilin H and 
L in a mouse ear delayed hypersensitive reaction. Thus, both compounds efficiently 
reduce the ear swelling as well as the inflammatory cell infiltration. These results provide 
more evidences for their potential therapeutic application in immune-related diseases of 
Spongionella compounds.
Keywords: Spongionella sp., cD147, cyclophilin a, inflammation, chemotaxis
inTrODUcTiOn
Cyclophilins (Cyps) are proteins ubiquitously distributed intracellularly in all prokaryotic and 
eukaryotic cells. The description of cyclophilin (Cyp) inhibitors began in 1970 when cyclosporine A 
(CsA) was first isolated from the fungus Tolypocladium inflatum, and then its inhibitory effect over 
T-cell reactivity was observed (1). Nevertheless, it was not until 1984 when the first Cyp, specifically 
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cyclophilin A (Cyp A), was purified from bovine thymocytes, 
and it was confirmed as the primary intracellular receptor of the 
immunosuppressive drug CsA (2). This protein family has been 
shown to possess peptidyl-prolyl cis-trans isomerase (PPIase) 
activity and plays an important role intracellularly in protein 
folding and trafficking (3). Although it was initially believed that 
Cyps exist only as intracellular proteins, nowadays it is known 
that some members of this family can be secreted to the extracel-
lular media where they play different functions as mediators of 
intra and intercellular communication. The first Cyp discovered 
in extracellular fluids was Cyp B, specifically in milk and plasma 
(4). Shortly after, it was discovered that Cyp A is secreted to 
extracellular media in response to inflammatory stimuli (5).
Leukocyte trafficking and recruitment is a critical component 
in host immune surveillance and inflammation-mediated pathol-
ogy. The main regulators of leukocyte trafficking are chemokines, 
a family of chemoattracting cytokines that control cell migration 
and adhesion (6). However, other factors like extracellular Cyp A 
have been described by different reports as potent chemotactic 
response inducers in human monocytes, neutrophils, eosinophils, 
and T cells either by in vitro or in vivo assays (7). Secreted Cyp 
A can initiate signaling response in target cells. In this sense, the 
binding protein receptor that transduces Cyp A-activated signal 
into target cells is the CD147 receptor also called extracellular 
matrix metalloproteinase inducer (EMMPRIN) or Basigin (8). 
Moreover, Cyp A is not only the ligand for CD147 receptor but 
also is responsible for the translocation of CD147 to the mem-
brane surface (9).
Although CD147 receptor is expressed in leukocytes and 
its implication has been investigated in deep in inflammatory 
response, it is ubiquitously expressed in almost all studied cell 
types, such as hematopoietic, epithelial, endothelial, or tumor 
cells in different levels (10). In the case of tumor cells, CD147 
has multiple functions related with metastasis or angiogenesis, 
while in normal cells it is related with a wide range of processes 
as immune/inflammatory response (11). In an inflammatory 
process, the expression of CD147 is upregulated (12–14). The 
expression of this receptor can also be induced in vitro whether T 
cell is activated through its TCR by mitogens, such as lectins (15).
Sponges are aquatic organisms able to adapt to different envi-
ronments (16). A wide type of bioactive compounds had been 
isolated from these invertebrate animals (17). Anti-inflammatory, 
immunosuppressive, anticoagulant, antibacterial, antifungal, or 
anticancer effects had been associated to some molecules obtained 
from sponges (18). In this sense, bisnorditerpene Gracilin H, nor-
diterpene Gracilin A, 12-hydroxy derivative Gracilin L, and the 
diterpenoid 3′-norspongionlactone tetrahydroaplysulphurin-1 
were isolated from the marine sponge Spongionella gracillis. 
These compounds have shown interesting antioxidant effects 
and the inhibition of Alzheimer hallmarks (19, 20). In addition, 
Gracilin H, A, L, and Tetrahydroaplysulphurin-1 were able to 
form complexes with intracellular Cyps (21). In the case of Cyp A, 
Spongionella compounds showed a KD in the micromolar range, 
similar to CsA, a well-known Cyp A binder, and in the same 
way, they regulated transcriptional factors and the production of 
interleukin 2 (IL-2) (21, 22). Thus, these compounds could mimic 
other CsA effects related to the immune response. In this context, 
the aim of this work was to deeply study the modulatory effect of 
Spongionella-isolated compounds on Cyp A functions, different 
than calcineurin blockade, such as CD147 receptor expression 
and chemotaxis.
MaTerials anD MeThODs
chemicals
Human Cyp A Elisa kit was purchased from Novateinbio 
(Woburn, MA, USA); FITC Anti-Human CD147 (Ref-14781-
100T) and Isotype control IgG1 FITC (Ref-ICIGG1F-100T) was 
from Immunostep (Salamanca, Spain). QCM™ Chemotaxis 5 μm 
96-Well Cell Migration Assays was from Millipore (Germany). 
Percoll was obtained from Pharmacia (Uppsala, Sweden). Plastic 
tissue-culture dishes were from Falcon (Madrid, Spain). RPMI 
and fetal calf serum (FBS) were bought from Gibco (Glasgow, 
UK). Methanol (HPLC grade) was supplied by Merck (Barcelona, 
Spain). The human Pan T cell Isolation Kit (Ref-130-096-535) 
and the monoclonal antibody to human CD3, clone BW264/56, 
FITC (Ref-130-098-162) were purchased from Miltenyi Biotec 
(Germany). Human IL-2 ELISA kit was obtained from Invitrogen 
(Spain). Active human Cyp A full-length protein was from Abcam 
(UK). Paraformaldehide (PFA) was from Aname (Madrid, 
Spain). CsA (purity ≥98.5%), 1-Fluoro-2, 4-dinitrobenzene 
(DNFB), poly-l-lisine, α-chymotrypsin from bovine pancreas, 
N-succinyl–Ala–Ala–Pro–Phe–p-nitroanilide, and the rest of 
chemicals and reagents were obtained from Sigma-Aldrich 
(Madrid, Spain). The composition of saline solution (PBS) used 
for human T lymphocytes purification was (in millimolar) 137 
ClNa, 8.2 Na2HPO4, 1.5 KH2PO4, 3.2 KCl, and 2 EDTA. The 
composition of Umbreit saline solution was (in millimolar) NaCl 
119, MgSO4 1.2, NaH2PO4 1.2, NaHCO3 22.85, KCl 5.94, and 
CaCl2 1. Glucose 1 g L−1 was added to the medium. The pH was 
equilibrated between 7.2 and 7.3. Stock solutions of drugs were 
done in dimethyl sulfoxide (DMSO).
Acetonitrile and methanol were supplied by Panreac 
(Barcelona, Spain). All solvents employed in this work were of 
HPLC or analytical grade, and the water was distilled and passed 
through a water purification system (Milli-Q, Millipore, Spain). 
Formic acid was purchased from Merck (Darmstadt, Germany). 
Ammonium acetate was from Fluka (Sigma-Aldrich, Spain).
human T lymphocytes isolation
Peripheral lymphocytes were isolated from human fresh heparin-
ized blood from healthy volunteers as previously described (23). 
The blood was diluted in the same proportion with PBS plus 
EDTA 2 mM previously equilibrated at room temperature. Also, 
4 mL of diluted blood were carefully placed over 3 mL of isotonic 
percoll (57.5%) previously disposed in 10-mL tubes, avoiding the 
mixture of phases. The tubes were centrifuged at 3000 rpm, 25 min 
at room temperature. After centrifugation, different phases were 
obtained, and only the fraction containing the population of lym-
phocytes was collected and washed three times with PBS–EDTA 
to remove percoll at 1500 rpm, 10 min, and room temperature. 
Lymphocyte purity was always higher than 80%. T lymphocytes 
were purified from this population with a Pan T cell Isolation 
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Kit. This is an indirect magnetic labeling system for the isolation 
of untouched T cells. T cell purity was always higher than 95%. 
Assessment of cell purity was performed by flow cytometry by 
using a monoclonal antibody to human CD3 labeled with FITC. 
Viability (>95%) was determined by trypan blue exclusion. Pure 
T cells were maintained in RPMI 1640 plus 10% FBS and plated 
in 24 plastic tissue-culture dishes in humidified 5% CO2 and 95% 
air atmosphere at 37°C.
cD147 receptor expression in  
T lymphocytes
For CD147 measurements, T cells were pretreated with Spongionella 
compounds or CsA 2 h before Con A (50 μg mL−1) stimulation for 
48 h. After this, cells were centrifuged at 2000 rpm, 5 min, and 4°C 
to remove RPMI 1640 culture medium. Next, cells were washed 
twice with PBS–BSA 2% (2000  rpm, 5  min, 4°C), and a final 
concentration of 1 × 106 cells in 50 μL were incubated with 20 μL 
of FITC Anti-Human CD147 for 90 min in darkness and at 4°C in 
a automatic shaker. After this time, T cells were washed twice with 
PBS to remove the dye (2000 rpm, 5 min, 4°C) and resuspended 
in a final volume of 60 μL of PBS with 1% paraformaldehyde and 
kept on ice until use. Cells were attached onto 22-mm glass cov-
erslips treated with poly-l-lysine for 10 min. FITC excitation and 
emission are 494/520 nm, respectively. Lasers used for excitation 
and emission were 476 and 510 with the confocal laser-scanning 
microscope Nikon D-Eclipse C1. The images were collected using 
the 40× immersion objective (Nikon).
For flow cytometry assays, cells were resuspended in a final 
volume of 2 × 106 cells in 100 μL of PBS with 1% paraformalde-
hyde and kept on ice until use and analyzed by flow cytometry 
technique. The IDEAS ImageStream Analysis software was used 
to analyze the data obtained from the measurements of the fluo-
rescence intensity.
cyp a release Measurements
For Cyp A measurements, 2 × 106 cells in a volume of 200 μL 
were seeded in a 96-well plate. Human T cells were pretreated 
with Spongionella compounds or CsA for 2 h. Then, cells were 
stimulated with Con A at 50 μg mL−1 for 48 h to induce Cyp A 
release to the culture medium. After the incubation time, cells 
were centrifuged, and the cell culture was collected and assayed 
immediately by using Human Cyclophilin A Elisa kit. The 
amount of Cyp A present in the culture medium was measured 
in a spectrophotometer at the wavelength of 450 nm.
chemotaxis assays
The chemotaxis assays were conducted using purified human 
T lymphocytes. The chemotactic activity was assessed using 
QCM™ Chemotaxis 5  μm 96-Well Cell Migration Assays 
(Millipore) composed by two compartments separated by a 5-μm 
membrane. Treated cells (200,000 per condition) were located on 
the top of the insert membrane in RPMI 1640 culture medium 
in the absence of FBS for 24 h at 37°C and 5%CO2. During this 
time, cells can migrate to the feed chamber, located under the 
insert membrane, where the medium contains the chemoattract-
ant human recombinant Cyp A (50  ng  mL−1). After 24  h, the 
migratory cells were collected in 150 μL of medium that contains 
the feed chamber plus migratory cells on the bottom of the insert 
membrane (cells that cross the membrane but stay adhered to the 
bottom part) that are dissociated from the membrane after 30 min 
incubation with Cell Detachment Buffer. A volume of 75 μL of 
dissociated cells plus 75 μL of cells from the migration feeder are 
mixed. These cells are subsequently incubated for 15 min at room 
temperature with Lysed buffer that contains the CyQuant GR dye. 
After this time, the fluorescence of lysed T cells was determined 
in a microplate reader at 480 nm excitation and 520 nm emission 
in a spectrophotometer plate reader.
Pharmacokinetic assays
Swiss mice colonies were kept in the facilities of the animal care 
centre of Universidad de Santiago de Compostela (Spain). All ani-
mal protocols were carried out following the principles approved 
by the Institutional Animal Care Committee of the Universidad 
de Santiago de Compostela. For the experiments, three animals 
per group were used. The animals were fed ad libitum and main-
tained under controlled conditions with a temperature of 24°C, 
humidity 40–80%, and 12-h light and dark cycle. All procedures 
were in strict accordance with the Guide for the Care and Use of 
Laboratory Animals. All specimens were about 12 weeks old and 
weighed 20–25 g.
Mice were intraperitoneally (IP) injected with CsA or 
Spongionella compounds at 0.4  mg  kg−1 and were housed in a 
metabolic cage where the urine and feces were collected at 1 and 
24 h. Animals were sacrificed and blood, urine, feces samples, and 
brain were collected.
sample extraction
Whole blood samples were collected in tubes, stored at −80°C 
until analysis, and thawed to room temperature before use. Tissue 
samples (brain) were weighed and homogenized in 1 mL of phos-
phate buffered saline 10 mM (PBS) using a manual homogenizer 
and centrifuged at 10,000 × g for 10 min. The supernatant was 
separated from the pellet and frozen at −80°C until analysis and 
thawed to room temperature before use. In the case of feces, 
1 mL of PBS was added to the samples and mixed for 2 min to 
homogenate with the PBS. After these, feces were centrifuged at 
10,000 × g, and the supernatant was stored at −80°C. In the case 
of urine, per 100 μL of sample, 20 μL of methanol was added and 
also stored at −80°C. Afterward, all samples were processed with 
the same method. To 100 μL of mixture, 40 μL of methanol were 
added and vortex-mixed for 30 s. Then, 10 μL of 10% trichloro-
acetic acid aqueous solution were added and vortex-mixed for 
30 s. Later, 50 μL of acetonitrile were added to the mixture and 
vortex-mixed for 1 min. Samples were centrifuged at 14,500 × g 
for 15 min, and the supernatant was filtered with 0.22-μm filter 
and injected (5 μL) in the LC column.
The recuperation rate of the method was calculated as 83% 
recovery for CsA and 84% recovery for Gracilin H and L, except 
in blood with a 60% recovery.
lc–Ms/Ms analysis
For CsA analysis, a 1290 Infinity ultra-high-performance liquid 
chromatography (UHPLC) system coupled to a 6460 Triple 
Table 1 | Quantification of csa, gracilin h, and gracilin l obtained by UPlc-Ms method in four matrixes of blood, brain, urine, and feces at 1 and 24 h 
after iP injection.
blood (ng/100 μl) brain (ng/brain) Urine (ng/ml) Feces (ng/g)
1 h 24 h 1 h 24 h 1 h 24 h 1 h 24 h
CsA 419.87 ± 45.4 9.3 ± 0.3 36.1 ± 6.8 9.2 ± 0.3 441 ± 112 62.3 ± 19.7 80.47 ± 27.6 14.5 ± 2.8
Gracilin H nd nd nd nd 6 ± 3.3 3.5 ± 1.5 38.1 ± 19.4 <LOQ
Gracilin L nd nd nd nd 52.23 ± 7.3 13.29 ± 7.3 nd nd
LOQ, limit of quantification; nd, not detected.
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Quadrupole mass spectrometer (both Agilent Technologies, 
Waldbronn, Germany) was used. Chromatographic separation 
was performed at 50°C, the injection volume was 5 μL, and flow 
rate of 0.4 mL min−1 using a column AQUITY UPLC BEH C18 
(2.1 mm × 100 mm, 1.7 μm, Waters, Spain). The nitrogen genera-
tor is a Nitrocraft NCLC/MS from Air Liquid (Spain). The mobile 
phase A was water with 0.1% formic acid and 2 mM ammonium 
acetate, and the mobile phase B was methanol. Chromatographic 
separation was performed by gradient elution starting with 80% 
B for 1.2 min, then increasing to 95% B for 4 min, this condition 
was held for 5 min, and reduced afterward to 80% B over 0.2 min. 
This proportion was maintained for 1.8 min until the next injec-
tion to equilibrate the system. Source conditions were optimized 
to achieve the best sensitivity for CsA. A drying gas temperature 
of 250°C and a flow gas of 5 L min−1, sheath gas temperature of 
250°C, a sheath gas flow of 11 L min−1, and nebulizer gas pres-
sure of 30 psi were used. The capillary voltage was set to 4500 V 
with a nozzle voltage of 500 V. The fragmentor was 165 for m/z 
1219.87 and 140 for m/z 601.93, and the cell accelerator volt-
age was 4 V. The collision energy, optimized using MassHunter 
Optimizer software, was 12 V for m/z 1219.87 and 32 and 60 V 
for m/z 601.93. Analysis was carried out using electrospray 
ionization (ESI) and multiple reactions monitoring (MRM) in 
positive mode (Table 1). Three product ions were analyzed, one 
for quantification and another for confirmation. The transitions 
employed were m/z 1219.87 > 1202.8, m/z 601.93 > 156.1/100.1. 
For CsA standard, an eight-points calibration curve among the 
range 3.91–500 ng mL−1 was done. The limit of detection (LOD) 
was 1.5  ng  mL−1, and the limit of quantification (LOQ) was 
3.91 ng mL−1.
lc–PDa–iT–TOF analysis
For Gracilins analysis de UPLC-IT-TOF was used. The UPLC 
system, from Shimadzu (Kyoto, Japan) consists of two pumps 
(LC-30AD), autoinjector (SIL-10AC) with refrigerated rack, 
degasser (DGU-20A), column oven (CTO-10AS), and a system 
controller (SCL-10Avp). The system is coupled to an IT–TOF–
MS system with an ESI interface (Shimadzu, Kyoto, Japan) and 
Photodiode Array UV-Vis detector (SPD-M20A). The nitrogen 
generator is a Nitrocraft NCLC/MS from Air Liquid (Spain). The 
molecules were separated using a column AQUITY UPLC BEH 
C18 (2.1 mm× 100 mm, 1.7 μm, Waters, Spain) at 35°C. Mobile 
phase A was 100% water with 0.1% formic acid. Mobile phase B 
was acetonitrile 100%, containing 0.1% formic acid. The gradient 
run started at 50% B (0–7 min), raised to 100% B (7–8 min), held 
to 100% B (8–9 min), returned to 50% B (9–9.5 min), and held to 
50% B (9.5–12 min). The samples in the autosampler were cooled 
to 4°C, and injection volume was 5 μL. The MS method was oper-
ated in positive mode with the following ESI source conditions: 
nebulizing gas flow, 1.5 L min−1, heat block temperature and CDL 
temperature, 200°C, and detector voltage, 1.65 kV. The molecules 
were analyzed using an ion accumulation time of 50 ms. The cell 
of PDA detector maintained at 30°C. The range of wavelength of 
the PDA detector was set at 190–600 nm because of the deuterium 
(D2) lamp used.
For Gracilin H and Gracilin L standard, an eight-points cali-
bration curve among the range 3.91–500 ng mL−1 was done. The 
LOD was 1.5 ng mL−1, and the LOQ was 3.91 ng mL−1.
DnFb-induced Delayed-Type 
hypersensitivity reaction
The DNFB-induced delayed-type hypersensitivity (DTH) reac-
tion assay was performed as previously described (24). On days 
0 and 1, mice were sensitized by skin painting on the abdomen 
with 25 μL of 0.5% DNFB dissolved in acetone–olive oil (4:1). 
Vehicle, CsA (used as the positive reference substance), or 
Spongionella compounds were IP administered to each group 
(n = 3) on five consecutive days (days 2–6) at 0.4 mg kg−1. On 
day 6, mice were challenged by the application of 20 μL of 0.2% 
DNFB on inner and outer surfaces of the right ear, while the left 
ear was used as control of normal tissue. After 24 h, the differ-
ence in thickness between the left and the right constant area of 
the ear was measured with a caliper. The increment rate of ear 
swelling was expressed as follows: % of increment = [(thickness 
of the right ear − thickness of the left ear)/thickness of the left 
ear] ×  100. Mice were sacrificed, and the right ear tissue was 
fixed by immersion in 10% buffered formalin solution. Then, 
samples were embedded in paraffin according to standard 
laboratory procedures, and (3 μm) sections were mounted onto 
silanized slides and dried overnight at 37°C. Tissue sections were 
routinely stained with Mayer’s hematoxylin and eosin (H-E) 
dyes following standard procedures for routine histological 
evaluations.
statistical analysis
All experiments were carried out by duplicate a minimum of 
three times. Results were analyzed by using one-way analysis 
of variance ANOVA with Dunnett’s post  hoc analysis. Also, 
p values <0.05 were considered statistically significant. All 
results were expressed as the mean ±  SEM of three or more 
experiments.
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resUlTs
In a previous work, we demonstrated that Gracilin H, A, L, and 
Tetrahydroaplysulphurin-1 were able to form a complex with 
intracellular Cyp A. All Spongionella compounds showed a KD 
in the micromolar range, similar to CsA, a well-known Cyp A 
binder (22). Thus, considering these previous results we studied 
in which extent Spongionella compounds modulate other func-
tions such as extracellular Cyp A and CD147 receptor functions.
In normal tissues, T lymphocytes ubiquitously express 
CD147 receptor. Nevertheless, under pathological situations, T 
cells can overexpress this receptor on its surface (25). In addi-
tion, the translocation and expression of CD147 receptor to the 
membrane is mediated by Cyp A, and it is greatly reduced after 
CsA treatment (25). Therefore, we first checked the effect of 
Spongionella compounds over CD147 expression. The increase 
of CD147 expression can also be in vitro induced after T lym-
phocytes activation (15). In this way, we first measured the 
baseline expression of CD147 in non-activated versus activated 
T lymphocytes by confocal microscopy with Anti-Human 
CD147 FITC-labeled. As Figure 1H shows, while in resting cells 
the average of fluorescence intensity corresponding to CD147 
expression was 225 ±  22.4 fluorescence units, in T cells, after 
48  h stimulation in the presence of Con A, the fluorescence 
was significantly increased to 550.79 ± 73.1 fluorescence units 
(p < 0.05), that is 2.44 times. Therefore, in vitro Con A-activated 
T cells expressed higher levels of CD147 than resting cells. A 
representative microscopy image shows the difference in fluo-
rescence intensity in activated (brightly fluorescent) (Figure 1B) 
versus non-activated T cells (Figure  1A). When T cells were 
pretreated with CsA (used as positive control) 2 h before Con 
A stimulation (Figures 1C,H), the fluorescence intensity units 
decreased to 185.7 ± 1.98 (p < 0.001), similar levels than rest-
ing cells. Straightaway, the effect of Spongionella compounds 
pretreatment before Con A activation was also tested. With 
similar potency than CsA, all compounds were able to reduce the 
fluorescence intensity to control cell levels; Gracilin H, A, L, and 
Tetrahydroaplysulphurin-1 decreased the fluorescence intensity 
unit values to 206.23 ± 25.2 (p < 0.01), 206.24 ± 28.3 (p < 0.001), 
201.34 ± 32.2 8 (p < 0.001), and 255.27 ± 11.6 (p < 0.01), respec-
tively (Figures 1D–H). Therefore, Spongionella compounds were 
able to efficiently reduce the expression of CD147. These results 
were confirmed by flow cytometry (Figure 2A). The fluorescence 
of Anti-Human CD147 labeled with FITC was measured in 
channel 2, thus the intensity in this channel is proportional of 
CD147 receptor expression. As Figure 2B shows, 7.84 ± 1.31% of 
control cells constitutively express CD147 receptor, while in Con 
A-treated cells this population was increased to 18.94 ±  2.1% 
(p < 0.001). When cells were treated with CsA or Spongionella 
compounds before activation, the percentage of CD147 posi-
tive cells significantly decreased to 11.9 ± 2.22% (p < 0.05) in 
the case of CsA and to 7.41 ± 1.6% (p < 0.01) and 6.54 ± 1.46 
(p <  0.01) in the case of Gracilin A and L, respectively, while 
Tetrahydroaplysulfurin-1 incubation produced the lower reduc-
tion of CD147 positive cells, 16.17 ± 0.95% (p < 0.05). Therefore, 
Spongionella compounds significantly reduce the presence of 
CD147 receptor on the cellular membrane of T cells.
Cyclophilin A acts as a strong chemotactic substance. In the 
case of inflammatory cells, under pathological situations, the cells 
can secrete this protein to the medium (7). Once in the extracel-
lular medium, Cyp A acts recruiting and attracting to the damage 
tissues the inflammatory cells where they develop their functions. 
Thus, T cells are also attracted, and CD147 receptor acts as Cyp A 
binder (26). We first checked the differences in secretion of Cyp A 
to the extracellular medium between activated and resting T cells. 
As Figure 3 shows, there was a significant increase in the Cyp A 
release from activated T cells to the medium, 2.97 ± 0.72 ng mL−1 
from control cells and 6.8 ± 0.47 ng mL−1 (p < 0.01) from Con 
A-activated T lymphocytes. When the cells were 2 h pretreated 
with CsA or Spongionella compounds, the Cyp A release was 
decreased almost to control conditions, although in the case of 
Tetrahydroaplysulphurin-1, the decrease was not significant.
The next question was the correlation between CD147 
expression and the Cyp A-mediated immune response. Thus, the 
capacity of human Cyp A to induce migration in populations of 
T lymphocytes was checked. In these studies, human T lympho-
cytes were stimulated in vitro with Con A for 48 h to generate 
populations containing high CD147 expression. After activation, 
T cells were placed in the upper part of a migration chamber 
with human Cyp A (50 ng mL−1) in the bottom part. As Figure 4 
shows, from 200,000 cells, 34,428 ± 937.5 of non-stimulated cells 
freely migrated to the bottom chamber. When Cyp A was present 
in this chamber, 58,589 ±  9161 cells were able to migrate. In 
these conditions, if the cells were previously activated with Con 
A, 104,418 ±  9342 cells were detected in the bottom chamber. 
This number was significantly decreased to control values, 40,000 
cells (p <  0.001), when the cells were pretreated with CsA or 
Gracilin L, and to 63,768 ± 6367 cells (p < 0.01) after Gracilin 
A pretreatment before Con A stimulation. However, Gracilin 
H and Tetrahydroaplysulphurin-1 did not produce a significant 
reduction of T cells migration.
Next, we tested the effects of CsA and two Spongionella com-
pounds in vivo, after a reaction of hypersensitivity in mice. The 
choice of compounds was done according to the results obtained 
in the migration assays, Gracilin H as representation of no effect 
over T cell migration assay and Gracilin L as representative 
of complete inhibition over this response. First, the pharma-
cokinetic behavior of Gracilin H and L as well as CsA after IP 
administration was checked in order to know if the compounds 
were absorbed through this administration route. In this way, 
mice were IP injected, and urine, feces, brain, and blood samples 
were analyzed. As Table 1 shows, after 1 h CsA treatment, the 
compound was detected in all the samples analyzed, although 
the highest amount was found in blood and urine samples. After 
24-h treatment, the amount detected in blood and brain samples 
decreased, while in urine and feces, CsA was still high. In the 
case of Gracilins, both compounds were present in urine samples 
after 1- or 24-h treatment, while only Gracilin H was detected 
in feces. These results pointed to IP as a correct dosage route for 
these compounds.
Next, CsA and both Gracilins were tested on ear swelling after 
a DTH reaction. After 4–8 h from the last sensitization, DNFB-
treated animals experimented marked edema and vasodilatation 
on the sensitized ear (data not shown). All animals were sacrificed 
FigUre 1 | effect of csa or Spongionella compounds on cD147 receptor levels in human T lymphocyte membrane stimulated with con a. Confocal 
microscopy representative images from the experiments that correspond to (a) untreated control cells, (b) human T lymphocytes stimulated with Con A 
(50 μg mL−1) for 48 h, (c) human T lymphocytes pretreated for 2 h with CsA (0.2 μM) before Con A stimulation for 48 h, or (D) Gracilin H (1 μM), (e) Gracilin A 
(1 μM), (F) Gracilin L (1 μM), or (g) Tetrahydroaplysulphurin-1 (1 μM), (h) fluorescence intensity of human T lymphocytes pretreated for 2 h with CsA (0.2 μM), 
Gracilin H (1 μM), Gracilin A (1 μM), Gracilin L (1 μM), or Tretrahydroaplysulphurin-1 (1 μM) and then with Con A (50 μg mL−1) for 48 h. All values are presented as the 
mean fluorescence intensity and are compared to that of T lymphocytes treated with Con A 50 μg mL−1 alone by ANOVA statistical analysis followed by post hoc 
Dunnet’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001, or between control cells and Con A-treated cells #p < 0.05. Data are the mean ± SEM of three independent 
experiments carried out by duplicate.
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24  h after challenging. As shown in Figure  5, DNFB-treated 
animals were considered as the maximum% of ear swelling. 
Comparing CsA, Gracilin H-, or L-treated animals plus DNFB 
versus DNFB group, different responses on the % of ear swell-
ing were observed. In the presence of CsA, ear swelling was 
78.86 ± 16.07% (p < 0.05) reduced, similar to the effect observed 
FigUre 2 | effect of csa or Spongionella compounds on plasma membrane levels of cD147 receptor in human T lymphocytes stimulated with con a. 
(a) Representative cellular images and histograms of the CD147 receptor expression of untreated human T lymphocyte control cells, Con A (50 μg mL−1) for 48 h 
treated cells and human T lymphocytes pretreated for 2 h with CsA (0.2 μM) or Spongionella compounds (1 μM) before Con A stimulation for 48 h. Brightfield 
images are represented in channel 4, and FITC intensity images are shown in channel 2. (b) Percentage of cells with CD147 expression in plasma membrane after 
Con A or CsA (0.2 μM), Gracilin H, A, L, and tetrahydroaplysulfurin-1 pretreated for 2 h with at 1 μM before Con A stimulation for 48 h. All values are presented as 
the percentage of fluorescence intensity and are compared to that of T lymphocytes treated with Con A 50 μg mL−1 alone by ANOVA statistical analysis followed by 
post hoc Dunnet’s t-test. *p < 0.05, **p < 0.01, or between control cells and Con A-treated cells ###p < 0.001. Data are the mean ± SEM of three independent 
experiments (10,000 cells were analyzed in each experiment).
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with Gracilin L with a 88.37 ± 5.73% (p < 0.05) reduction, while 
the smaller effect was observed with Gracilin H that produced a 
reduction of a 64.75 ± 2.79% (p < 0.05).
Furthermore, histological changes in ear tissues were also 
checked. Swelling of hypodermal tissue and the infiltration of 
inflammatory cells were observed in the ear section by histological 
FigUre 5 | In vivo effect of csa or Spongionella compounds on the 
ear thickness 24 h after DnFb challenge. Mouse ear thickness calculated 
as the percentage of increment rate (thickness of the challenged ear minus 
the baseline thickness of the unchallenged ear) of ear swelling of DNFB-
sensitized animals and compared to CsA (0.4 mg kg−1), Gracilin H 
(0.4 mg kg−1) or Gracilin L (0.4 mg kg−1) treated animals. *p < 0.05. Data are 
mean ± SEM of three mice per group.
FigUre 4 | Quantification of human T lymphocytes migration. Human 
T lymphocytes were pretreated for 2 h with CsA (0.2 μM), Gracilin H (1 μM), 
Gracilin A (1 μM), Gracilin L (1 μM), or Tetrahydroaplysulphurin-1 (1 μM), and 
then with Con A (50 μg mL−1) for 48 h. After the treatment, T cells were 
placed in the migration chamber for 24 h in the presence of the chemotactic 
agent Cyp A (50 ng mL−1). Control of non-activated T cells in the presence or 
absence of Cyp A is also included. All values are shown as the difference 
between Con A migratory cell number versus Con A and CsA or 
Spongionella compounds treated cells in the presence of Cyp A by ANOVA 
statistical analysis followed by post hoc Dunnet’s t-test. *p < 0.05, 
**p < 0.01, ***p < 0.001, or Con A-treated cells in the presence of Cyp A 
versus control cells ###p < 0.001 or Con A-treated cells versus non-stimulated 
cells in the presence of Cyp A +p < 0.05. Mean ± SEM of three independent 
experiments.
FigUre 3 | effect of csa or Spongionella compounds on cyp a 
release in human T lymphocytes stimulated with con a. Human T 
lymphocytes were pretreated for 2 h with CsA (0.2 μM), Gracilin H (1 μM), 
Gracilin A (1 μM), Gracilin L (1 μM), or Tetrahydroaplysulphurin-1 (1 μM), and 
then with Con A (50 μg mL−1) for 48 h. All values are shown in percentage 
with respect to Con A-treated cells and compared to cells treated with CsA 
or Spongionella compounds by ANOVA statistical analysis followed by 
post hoc Dunnet’s t-test. *p < 0.05, **p < 0.01 or Con A-treated cells versus 
control cells ##p < 0.01. Mean ± SEM of three independent experiments.
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analysis of H-E staining. As Figures 6B,B’ show, DNFB-treated 
cells significantly increased the ear thickness comparing to non-
sensitized animal (Figures 6A,A’) as well as the number of inflam-
matory cells. Nevertheless, CsA-treated animals (Figures 6C,C’) 
mitigated DNFB-induced ear swelling, and inflammatory cells 
infiltration was observed. In a similar way, mouse treated with 
Gracilin H (Figures 6D,D’) and Gracilin L (Figures 6E,E’) under-
went a reduction in ear inflammation as well as inflammatory cell 
infiltrates compared with DNFB-treated animals.
DiscUssiOn
In previous results, we observed that the four Spongionella-
isolated compounds bind to Cyp A with a similar binding affinity 
than CsA, mimicking the mechanism of action of this calcineurin 
inhibitor (22). Cyp A is a protein implicated in multiple processes, 
such as protein folding, trafficking, and transport (9). All these 
functions are related with the isomerase activity and are showed 
by all family members of Cyps (27). Thus, the expression of differ-
ent type of membrane receptors, such as asialoglycoprotein recep-
tor, insulin receptor, or receptor-type tyrosine–protein kinase, is 
regulated by this protein (28–31). The isomerase function of Cyp 
A is well documented for being inhibited by CsA (32). In this way, 
the transport and the expression of the surface membrane recep-
tors aforementioned were greatly reduced in different reports by 
CsA treatment (25). Because Spongionella compounds directly 
targeted Cyp A (22), the reduction of the presence of the surface 
membrane receptor CD147 in T cells produced by all Spongionella 
compounds could be related with the modulation of the isomerase 
activity of the protein. Other reports proved the existence of a Cyp 
A binding site in the transmembrane region at the residue Pro211 of 
CD147 that is responsible for the receptor transport to the surface 
(9, 26, 33). In the case of Spongionella compounds, once they 
FigUre 6 | histological changes of csa or Spongionella compounds treatment 24 h after DnFb–DTh-treated ear. Ear tissues were stained with H-E and 
observed using a microscope. The observations were made at a magnification of ×4 for figures (a–e) and ×40 for figures (a’,b,c,D’,e’). Microphotographs are 
representative from one animal. (a,a’), non-challenged control group; (b,b’), DNFB-sensitized group; (c,c’), 0.04 mg kg−1 CsA-treated animals; (D,D’), 
0.04 mg kg−1 Gracilin H-treated group; (e,e’), 0.04 mg kg−1 Gracilin L-treated group.
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bind to Cyp A, they could modulate the trafficking of CD147 in a 
similar way than CsA. Moreover, soluble factors such as epidermal 
growth factor (EGF) or various inflammatory mediators such as 
interleukins have been shown to regulate CD147 transcription 
and translocation (11, 16, 18). Therefore, the inhibitory effect on 
EGF receptor and over IL-2 production by the four Spongionella 
compounds described in previous papers could be also under the 
reduction of the presence of CD147 in the cell surface (1, 22). On 
the other hand, it is well documented that Cyp A can be secreted to 
the extracellular medium as a response of the cell to stress (34, 35). 
In in vitro conditions, the release of Cyp A from the cytosol can be 
induced with lectins by activating the intracellular machinery of 
the T cells (34). Thus, we observed that once T cells were stimu-
lated with Con A, they release Cyp A to extracellular medium. 
Nevertheless, with the exception of Tetrahydroaplysulphurin-1, 
Gracilins H, A, and L were able to efficiently reduce the secretion 
of Cyp A to extracellular environment. Reactive oxygen species 
(ROS) induce stress stimulus in the T cell and therefore can 
induce Cyp A secretion as described by many researches (34, 36). 
In accordance to previous results published with mouse cortical 
neurons, all Spongionella compounds were able to protect the 
cell against ROS insults by increasing nuclear factor E-related 
factor 2 levels in the nucleus, and consequently the antioxidant 
pathway that protects the cell is activated (19). Thus, such reduc-
tion of Cyp A secretion could be explained by the protective 
effects of these compounds stimulating different enzymatic cell 
defense mechanisms. Moreover, in in vitro and in vivo assays, all 
Spongionella compounds had the ability to inhibit extracellular 
signal regulated kinases (ERK), directly related with the inhibition 
of Cyp A secretion (19, 34). Besides, the implication of Cyp A in 
the CD147 transport to the plasma membrane, Gracilin A, and 
Gracilin L efficiently avoids the T cell migration in the presence 
of Cyp A. The effect of both compounds can be mainly attribut-
able to the effect produced at intracellular level by reducing the 
expression of CD147 in the T cell surface and therefore decreasing 
the chemotactic effect for Cyp A when it is present in the extracel-
lular medium. In the case of Gracilin L, it showed approximately 
two times less affinity than Gracilin H for the same target (22). 
Nevertheless, the full inhibition observed with Gracilin L over T 
cell migration comparing to the absence of effect of Gracilin H 
would not necessarily be associated with the affinity for the Cyp 
A, considering that we check the binding capacity with SPR on 
Cyp A, nevertheless, with this technique we cannot know the 
region where the compounds exactly bind to. Moreover, in in vivo 
experiments, both compounds disclosed a similar effect over ear 
swelling. This result can be explained by the effect of Gracilin H 
on other Cyps like Cyp B that is also involved in the inflamma-
tory process (37). However, the effect of Gracilin H over other 
enzymes, transcription factors, or adaptor proteins, which induce 
a cascade of metabolic events result in the transcriptional activa-
tion of a large number of different pro-inflammatory genes (38). 
In fact, Gracilin H as well as Gracilin L reduced the expression of 
phosphorylated ERK in in vivo assays (20). In pharmacokinetics 
studies, we observed that CsA cross hematoencephalic barrier, 
in accordance with other researches, but it is detected 1 h after 
administration in a low concentration. However, in the case of 
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Gracilin H and L, the absence of both compounds in blood could 
be explained by the association of the compounds to plasmatic 
proteins. With the IT–TOF technique, the masses range is m/z 
50–5000, thus we could not detect the possible complex formed. 
Nevertheless, the presence in urine of Gracilin H as well as 
Gracilin L may point out a previous absorption and incorporation 
of the molecules to the bloodstream to reach the kidneys, where in 
order to being eliminated, they have to dissociate from the binded 
protein and are again in the equipe mass range. DTH reaction is 
usually regarded as a cell-mediated immune response and plays an 
essential role in the immune diseases. This is a pathologic response, 
type IV hypersensitivity reaction, involving T cell activation and 
the production of many cytokines (39). This type of hypersen-
sitivity reaction is well-modulated by immunosuppressive drugs 
that possess a strong anti-DTH activity. In previous papers, we 
observed that Spongionella compounds mimic the effect of CsA 
on calcineurin and the translocation of NFAT to the nucleus. 
NFAT is one of the transcriptional factors that induce a cascade 
of metabolic events, resulting in the transcriptional activation of 
large number of different genes (38). In this way, they prevent 
the production of IL-2. These findings pointed out Spongionella 
compounds as possible anti-inflammatory or immunosuppressive 
agents (22). In the present study, we have shown that Gracilin H 
and Gracilin L efficiently reduced DTH reaction in the same way 
as CsA. Histological analysis of ear swelling showed a significant 
decrease on white cells infiltration when mice were pretreated 
with Gracilins or CsA. Thus, this effect can be produced by several 
mechanisms, such as the reduction of cytosolic calcium increase 
or the translocation inhibition of NFAT to the nucleus due to 
the calcineurin phosphatase activity reduction, both effects that 
lead to IL-2 inhibition (19, 21, 22). In addition, the reduction of 
CD147 expression in the cell surface produces the reduction of 
the inflammatory cells activation and proliferation and also by the 
reduction of Cyp A secretion due to the activation of antioxidant 
defense mechanisms of the cell avoiding the cell migration previ-
ously described (19, 20).
In this report, we show the ability of Spongionella compounds 
to reduce the cell membrane expression of CD147 receptor, the 
inhibition of Cyp A secretion, and the blockade of cell migration 
in the presence of Cyp A chemotactic stimulus. In vivo experi-
ments confirmed the capacity of Gracilin H and Gracilin L to 
reduce mouse ear swelling, edema, as well as the early inflam-
matory cells, and among them T cells. The antioxidant and 
anti-inflammatory/immunosuppressive abilities described in 
previous works (19, 22) and the results obtained in the present 
research are good starting points for the promotion of Gracilins 
as valuable option for synthetic drug development in order to 
obtain new drugs and stem the problems that present some of the 
available drugs used with anti-inflammatory and immunosup-
pressive purpose.
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